Cik daudz dividendes maksā Shandong Weigao Group Medical Polymer Co 2024?
Saskaņā ar aktuālo informāciju no oktobris 2024, Shandong Weigao Group Medical Polymer Co pēdējo 12 mēnešu laikā izmaksāja kopējo dividendes summu 0,25 CNY pro akciju. Pie pašreizējā Shandong Weigao Group Medical Polymer Co kursa 4,65 CNY, tas atbilst dividendes ienesīgumam 5,29 %.
Dividendes tiek izmaksātas reizes gadā.
5,29 % Dividends rendite | = | 0,25 CNY Dividende | 4,65 CNY akciju cena |
|
Vai Shandong Weigao Group Medical Polymer Co dividende ir droša?
Shandong Weigao Group Medical Polymer Co palielina dividendes jau 1 gadus.
Pēdējo 10 gadu laikā Shandong Weigao Group Medical Polymer Co ir paaugstināts to par 14,777 % gadā.
Pēdējo piecu gadu laikā izmaksas palielinājās par 17,253 %.
Analisti prognozē, ka šajā tekošajā finanšu gadā gaidāms Dividendu pieaugums aptuveni 4,272%.
Shandong Weigao Group Medical Polymer Co Aktienanalyse
Ko dara Shandong Weigao Group Medical Polymer Co?
Shandong Weigao Group Medical Polymer Co Ltd is a globally operating company with headquarters in Weihai, China. It was founded in 1988 and has been listed on the Hong Kong Stock Exchange since 2004.
The company specializes in the production of medical polymer products and offers a wide range of products for various applications. Its business model is that of an integrated platform for research, development, manufacturing, and marketing of medical devices. Their customers include hospitals, medical practices, and distributors worldwide.
The company's portfolio includes products in the areas of infusion, blood transfusion, dialysis, surgery, anesthesia, first aid, and diagnostics. Both disposable and reusable products are available. With its offering, the company aims to contribute to improving the quality of healthcare and providing better outcomes for patients.
Shandong Weigao Group Medical Polymer Co Ltd is divided into three divisions: Medical Devices, Medical Consumables, and Biology. The Medical Devices division manufactures devices for use in anesthesia, surgery, resuscitation, and diagnostics. The Medical Consumables division includes products such as syringes, catheters, infusion and transfusion devices, disposable gloves, and wound dressings. The Biology division specializes in the development, manufacturing, and marketing of biopharmaceutical products, such as insulin.
The company's history is characterized by rapid expansion and continuous growth. The focus on R&D has played an important role in this. Through the use of advanced technologies, the company has acquired a multitude of patents in both China and other countries.
The company places a strong emphasis on quality assurance and has implemented a comprehensive quality control system. In addition, it aims to minimize its environmental impact and therefore operates according to the latest environmental standards.
In recent years, the company has established an international presence and opened subsidiaries in Europe and the USA. This demonstrates the company's desire to grow internationally and offer its products in more and more countries.
In summary, Shandong Weigao Group Medical Polymer Co Ltd is an innovative company specializing in the production of medical polymer products and biopharmaceutical products. It offers a wide range of products and is committed to a comprehensive quality control system and sustainability. With its international presence, the company aims to continue growing and offer its products worldwide. Shandong Weigao Group Medical Polymer Co ir viens no populārākajiem uzņēmumiem vietnē Eulerpool.com.Akcienu ieguldījumu plāni piedāvā investoriem pievilcīgu iespēju ilgtermiņā uzkrāt kapitālu. Viens no galvenajiem priekšrocībām ir tā sauktais Vidējās izmaksas efekts: ieguldot regulāri noteiktu summu akcijās vai akciju fondos, automātiski tiek iegādāts vairāk daļu, kad cenas ir zemas, un mazāk, kad tās ir augstas. Tas laika gaitā var novest pie izdevīgākas vidējās cenas par daļu. Turklāt akcienu ieguldījumu plāni nodrošina piekļuvi dārgām akcijām arī mazajiem investoriem, jo tiem var pievienoties jau ar nelielām summu. Regulāra ieguldījumu veikšana arī veicina disciplinētu ieguldījumu stratēģiju un palīdz izvairīties no emocionāliem lēmumiem, piemēram, impulsīvas pirkšanas vai pārdošanas. Turklāt investori gūst labumu no potenciālās akciju vērtības pieauguma un no dividendēm, kuras var reinvestēt, tādejādi pastiprinot procentu uz procentu efektu un līdz ar to investētā kapitāla augšanu.